Published on : Jul 24, 2014
Indian pharmaceutical company Strides Arcolab has received the approval of the USFDA to sell its transplant drug Tacrolimus in the US market. The capsule is an immune-suppressant that is used for preventing organ rejection that may occur in transplant surgeries of organs such as kidneys, heart or liver in some patients.
USFDA has allowed the sale of the tablets in 5 mg, 1 mg and 0.5 mg strength variants, the company states in a statement. The US market for the generic variant of the capsule is estimated to be nearly 676 million USD.
The production of the capsule will take place at the company’s Bangalore based oral dosage facility. The capsule will be marketed directly by Strides in the States.
Strides is an India based pharmaceutical company that focuses primarily on the development and manufacture of niche IP-led generic medicines and bio-medicines. It is also counted amongst the world’s largest manufacturers of soft gelatin capsules.